Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials. Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment. AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA ...

Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials. Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment. AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAV ...

文章核心观点 - Cassava Sciences公司宣布其阿尔兹海默症治疗药物simufilam的第三期临床试验数据将于2024年12月公布[1][2] - 公司还计划在2025年6月启动第二项临床试验,试验将采用一比一比一的随机分组方式,包括两种剂量的simufilam和安慰剂[2] - Cassava Sciences公司董事会承诺将按时完成第三期临床试验,数据将由临床研究机构Premier Research和生物统计公司Pentara Corporation管理,公司在获得结果前不会知晓试验结果[3] 公司相关 - Cassava Sciences公司股票周一交易活跃,成交量超过760万股,远高于日均180万股的水平[4] - 公司股价上涨29%,但仍较年初下跌42%[5] 行业相关 - 投资者还关注其他公司如英伟达、星巴克和CrowdStrike的股市动态[6] - 投资者应谨慎关注市值较小和交易量较低的"penny stocks",因为这些股票容易被操纵[7]

文章核心观点 - 公司新任执行主席发表公开信,投资者对此反应积极 [1][2] - 新任执行主席表示公司正在寻找新CEO,并对公司的阿尔茨海默药物临床试验结果持乐观态度 [3][4][5] 公司概况 - 公司执行主席Rick Barry于2021年6月加入公司董事会,2024年7月被任命为执行主席 [3] - 公司正在寻找新CEO,此前的CEO Remi Barbier已于上周辞职 [3] 公司产品研发进展 - 公司计划于2024年12月公布其首个III期临床试验结果,并于2025年6月完成第二个III期临床试验 [5] - 公司的阿尔茨海默药物simufilam在II期临床试验中取得了积极的结果 [4] 投资评级 - 尽管今日股价大涨,但公司股价今年迄今仍下跌超过40% - 该股票仅适合风险偏好较高的投资者,因为III期临床试验结果仍存在不确定性 [6]

Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry suc ...

The biotech stock is feeling the heat from an indictment of a former consultant.Shares of Cassava Sciences (SAVA -2.43%) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava.Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam. These grants led ...

文章核心观点 - 美国司法部(DOJ)和证券交易委员会(SEC)正在对Cassava Sciences公司及其两名高级员工进行调查[2][3] - DOJ指控Cassava公司的前科学顾问王浩燕博士在向国立卫生研究院提交的拨款申请中存在欺骗性陈述,并操纵研究结果,包括伪造Western Blot图像[4][5][6] - Cassava公司的内部调查发现,在2b期临床试验中存在部分受试者被提前知晓试验结果的情况[8] - 尽管存在争议,Cassava公司仍在继续进行两项3期临床试验,并由独立机构负责数据和样本分析,不再涉及王博士及其实验室[11] 公司相关 - Cassava公司成立了特别调查委员会,负责监督外部律师进行调查,并监督公司对调查的披露[3] - Cassava公司发现的潜在问题包括2b期临床试验中部分受试者被提前知晓试验结果[8] - Cassava公司正在进行两项3期临床试验,约有1,900名患者参与,数据和样本分析由独立机构进行[11] 行业相关 - 王博士曾是Cassava公司的科学顾问,其研究与公司高级副总裁Lindsay Burns博士共同发现了simufilam[6] - 王博士的实验室曾负责2b期临床试验的最终生物分析,并获得了2,000美元的月度顾问费和股票期权[7] - Cassava公司之前曾报告了基于王博士生物分析的生物标志物显著改善,但排除了部分受试者的认知结果[10]

Shares of Cassava Sciences (NASDAQ:SAVA), which has an Alzheimer’s drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH). Indeed, Hoau-Yan Wang, a professor at the City University of New York (CUNY), was charged with fraud of over $16 million in grants.Cassava opened today at about $10.70 per share, far from its June 28 opening price of nearly $19 per ...

AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the government thr ...

文章核心观点 - 美国纳斯达克上市公司Cassava Sciences公司的前科学顾问王浩彦涉嫌欺骗美国国立卫生研究院(NIH),获得约1600万美元的研究经费[1][2] - 王浩彦的研究工作与公司的药物候选物simufilam和诊断测试的早期开发有关[2] - 王浩彦及其所在的公立大学医学院与公司的simufilam III期临床试验无关[3] 公司概况 - Cassava Sciences是一家纳斯达克上市公司[1] - 公司的领头药物候选物是用于治疗阿尔茨海默病的simufilam[3] 事件经过 - 联邦大陪审团起诉王浩彦涉嫌欺骗NIH[1] - 王浩彦曾担任公司的科学顾问,并在2017年至2021年期间获得约1600万美元的NIH研究经费[2] - 王浩彦的研究工作与公司的早期药物和诊断项目有关[2] - 王浩彦及其所在的公立大学医学院与公司的III期临床试验无关[3]